Shenzhen Geno-immune Medical Institute

This trial tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells that have two specific markers (PSMA and CD70). The study involves 60 patients with advanced cancers that have not responded to standard therapy. The goal is to se…

This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a …

This early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…

This early-phase trial tests a combination of CAR T cells designed to attack three different targets on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. Ten participants will receive infusions of these engineered immune cells to see if the treatment …

This study tests a personalized cell therapy using a patient's own immune cells, modified to target tumor-associated antigens, along with a dendritic cell vaccine. The goal is to see if this approach is safe for people with neurofibromatosis or schwannomatosis. Up to 100 particip…

This trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participa…

This trial tests a gene therapy for chronic granulomatous disease (CGD), a rare immune disorder that causes severe infections. The treatment uses a lentivirus to deliver a corrected gene into the patient's own stem cells, which are then infused back. Ten participants will be foll…

This study tests a new therapy using a patient's own immune cells, engineered to target a specific mutation found in diffuse midline glioma and DIPG, aggressive brain tumors. About 30 participants with recurrent or refractory disease will receive one to two infusions of these cel…

This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma. The therapy uses a patient's own immune cells that are modified in a lab to target and attack tumor cells. The trial will enroll 30 participants aged…

This study tests a new treatment for people with sarcoma that has come back or is advanced. It combines low-dose chemotherapy with special immune cells (CAR T cells) and vaccines to fight the cancer. The goal is to see if this approach is safe and helps shrink tumors or improve s…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This study tests a treatment where a patient's own immune cells are engineered in a lab to recognize and attack cancer. The goal is to see if these cells are safe and can shrink tumors. About 100 people with different cancers that have certain markers on their tumors can join. Th…

This early-stage trial tests whether a special type of stem cell, made from fetal cells, can safely help people with moderate to severe COPD. About 30 adults aged 40-80 who still have symptoms despite standard treatments will receive the cells. The main goal is to check for side …

This early-phase trial is testing a new type of cell therapy called 4SCAR-CD44v6 T cells for people with cancers that have a specific marker called CD44v6. The treatment involves taking a patient's own immune cells, engineering them to better recognize and attack cancer cells, an…

This early-stage trial tests a gene therapy for hemophilia B, a bleeding disorder. Ten patients will receive their own stem cells modified with a working gene for clotting factor IX. The goal is to see if it's safe and can help the body produce its own clotting factor, potentiall…

This study tests a new type of CAR T-cell therapy for people with B-cell leukemia that does not have the CD19 protein, often because it stopped responding to earlier CAR T treatment. The modified immune cells target six different markers on leukemia cells. The trial aims to see i…

This study tests a gene therapy given by IV for ADA-SCID, a rare and life-threatening immune disorder. The treatment uses a modified virus to deliver a working gene, aiming to restore the immune system. Ten participants will be monitored for safety and immune recovery over one ye…

This study tests a new treatment using special stem cells from fetal tissue for people with type 2 diabetes. The goal is to see if it is safe and can improve blood sugar control. About 30 adults with poorly controlled diabetes will receive the therapy and be monitored for side ef…

This study tests a new treatment for advanced ovarian cancer using a patient's own immune cells, which are modified in a lab to better attack the cancer. About 100 women with stage III or IV ovarian cancer who have already had treatment will receive these modified cells. The main…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This trial tests a gene therapy for X-linked adrenoleukodystrophy (X-ALD), a rare genetic disease that damages the brain. The therapy uses a modified virus to deliver a working gene into the body via spinal fluid and veins. About 30 patients aged 1 year and older will be enrolled…

This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…

This early-stage study tests a gene therapy for hemophilia A, a bleeding disorder. The treatment uses a modified virus to deliver a working gene into the patient's own stem cells, aiming to help the body produce the missing clotting factor VIII. Ten male participants aged 2 and o…

This study tests a new treatment for gastrointestinal cancers using a patient's own immune cells, which are engineered in a lab to better recognize and attack cancer. The goal is to see if this approach is safe and can shrink tumors. About 100 adults with certain cancer markers a…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. It is for people whose cancer has not responded to standard therapy. The goal is to see if this cell therapy is safe and can shri…

This trial tests a gene therapy for X-linked severe combined immunodeficiency (SCID-X1), also known as bubble boy disease. It involves a single IV injection of a modified virus to correct the faulty gene. The study aims to restore immune function and reduce infections in 10 patie…

This early-phase study tests a new type of universal CAR-T cell therapy for people with multiple myeloma that is in remission but hard to treat. The goal is to see if these cells are safe and can control the disease. About 20 participants will receive the treatment and be monitor…

This study tests a new combination of immune cells—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines—to fight advanced melanoma that has spread or come back after standard treatment. About 30 adults aged 18 to 75 with confirmed melanoma antigens will r…

This study tests a new treatment called multi-CAR T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to target multiple markers on leukemia cells. The g…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This early-stage trial tests a new cell therapy called 4SCAR-T for people with advanced bladder cancer that has spread and has no standard treatments left. About 20 participants will receive specially engineered immune cells designed to attack the cancer. The goal is to see if th…